CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease

scientific article published on 01 January 1999

CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/08916939908995386
P698PubMed publication ID10433078

P2093author name stringJ Delgado
R Perez
E Montero
L Falcon
Y Morera
J F Amador
P433issue2
P1104number of pages2
P304page(s)155-156
P577publication date1999-01-01
P1433published inAutoimmunityQ4826348
P1476titleCD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease
P478volume29

Reverse relations

cites work (P2860)
Q28295917A Ligand for CD5 Is CD5
Q37390483A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis
Q88716412CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action
Q38341487CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction
Q34874471Control of advanced cancer: the road to chronicity
Q36830250Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population
Q51820107Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple Method
Q38730494Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases
Q51075376Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Q48265755The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Q52935897[New developments in the systemic treatment of psoriasis].

Search more.